Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brivekimig · 2 trials · 2 indications
Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) is defined as ≥75% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count.
Mixed meal tolerance test MMTT stimulated C-peptide concentration is to be calculated from area under the concentration-time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Brivekimig dose regimen A | EXPERIMENTAL | Participants will receive Brivekimig dose regimen A. |
| Brivekimig dose regimen B | EXPERIMENTAL | Participants will receive Brivekimig dose regimen B. |
| Brivekimig dose regimen C | EXPERIMENTAL | Participants will receive Brivekimig dose regimen C. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Brivekimig matching placebo. |
| Brivekimig | EXPERIMENTAL | Participants will receive subcutaneous injection of brivekimig. |
| Name | Type | Description |
|---|---|---|
| Brivekimig | DRUG | * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection |
| Placebo | DRUG | * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection |
Inclusion Criteria: * Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline * Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Brivekimig is an investigational small molecule being studied for Type 1 Diabetes Mellitus and Hidradenitis Suppurativa. It is currently in Phase 2 clinical development for both conditions.
Brivekimig is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker symbol SNY.
Brivekimig is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
Brivekimig is being studied in two Phase 2 trials. NCT06812988 is evaluating it in Type 1 Diabetes Mellitus with an enrollment of 84 participants. NCT07170917 is evaluating it in moderate to severe Hidradenitis Suppurativa with an enrollment of 208 participants.
Yes, Brivekimig is being studied in Hidradenitis Suppurativa. The Phase 2 trial NCT07170917 is recruiting participants with moderate to severe Hidradenitis Suppurativa and is enrolling 208 participants across multiple countries.
Yes, Brivekimig is being studied in Type 1 Diabetes Mellitus. The Phase 2 trial NCT06812988 is active but not recruiting, with an enrollment of 84 participants aged 12 years and older.